European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-18

Development of a rapid cellular characterisation technology <br/>for use in the biopharmaceutical Industry

Cel

"Biopharmaceuticals have universal importance as effective therapeutics for many human diseases. Biopharmaceutical production employs living cells as ‘production machinery’ with the selection of the producing cell line, a critical step for an efficient industrial process. Current industry practices for cell selection are expensive and time-consuming. The proposed PM-CELL project will result in the development of a rapid cellular characterisation testing technology. The two-year project will result in an innovative 96-well micro-titre plate containing a unique array of analytes, which can be used to accelerate development and reduce manufacturing costs of biopharmaceuticals synthesised by mammalian cell lines. A successful project would result in cost savings for the SMEs’ customers in the bioprocessing industry and a more rapid translation of research to efficient drug production for human healthcare. The project would result in generation of a high value (economic and intellectual property) technology which would result in increased sales and assets to the SMEs. The SMES will then be well placed to take advantage of further development opportunities in the biopharmaceutical industry, which is actively looking for innovative solutions for manufacturing-cell selection in drug production."

Zaproszenie do składania wniosków

FP7-SME-2011
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

BSG-SME - Research for SMEs

Koordynator

TECHNO-PATH DISTRIBUTION
Wkład UE
€ 499 999,38
Adres
FORTHENRY BUSINESS PARK
BALLINA
Irlandia

Zobacz na mapie

Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Guy Mozolowski (Dr.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (7)